Elicio Therapeutics
ELTX
28 hedge funds and large institutions have $2.56M invested in Elicio Therapeutics in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0.15% less ownership
Funds ownership: 1.63% → 1.49% (-0.15%)
7% less funds holding
Funds holding: 30 → 28 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
36% less capital invested
Capital invested by funds: $3.98M → $2.56M (-$1.42M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$45.2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7.17K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.05K |
| 4 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$301K |
| 2 |
E
Ergoteles
New York
|
-$42.9K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$33.6K |
| 4 |
Renaissance Technologies
New York
|
-$19.1K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$11.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $2.17K | – | – | – |
|
27
Barclays
London,
United Kingdom
| $2.1K | – | – | – |
|
28
Wells Fargo
San Francisco,
California
| $86 | – | – | – |
|
|
PWAM
29
Park West Asset Management
San Francisco,
California
| – | -$301K | -37,072 | Closed |
|
|
E
30
Ergoteles
New York
| – | -$42.9K | -5,291 | Closed |
|
ELTX Hedge Fund Activity: Q1 2023 in Review
28 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q1 2023, worth a combined $2.56M — down 36% from $3.98M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ELTX and 0 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was CM Management, adding an estimated $45.2K. The largest seller was Park West Asset Management, exiting entirely with an estimated $301K sold.
- 28 institutional investors held Elicio Therapeutics (ELTX) as of Q1 2023, down from 30 in Q4 2022.
- Funds reported $2.56M of Elicio Therapeutics stock for Q1 2023, down 36% quarter-over-quarter.
- 0 funds opened new Elicio Therapeutics positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Elicio Therapeutics buyer in Q1 2023 was CM Management, an estimated $45.2K added.
- The largest Elicio Therapeutics seller in Q1 2023 was Park West Asset Management, an estimated $301K sold.
Based on aggregated 13F filings for Q1 2023.